Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
1–10 of 21 posts
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#2Incredibly stupid this is allowed and will become an avenue for rampant insider trading by biotech employees.
Look at the recent ChemoCentryx fraud where they settled for $35 million over misleading data and overstating results. This is going to encourage even more data manipulation.
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#3Given how much pressure there is to rig results with these markets, I see this going well.
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#4I can only imagine the company culture that enables and encourages creating gambling opportunities for this and the other troubling worldly events
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#5I have concerns regarding insider trading (as I certainly do regarding the stock market), but Kalshi's statement seems straightforward: "If you want to ban profiting from the failure of clinical trials, you would start with the stock market, where the financial incentive for this type of profit is orders of magnitude larger,"
I remember a time not too long ago when storm insurance was unavailable for large portions of the Gulf states. Horrible horrible people, betting on where hurricanes would make landfall, just horrible. /s
Explain to me like I'm 10 years old: what's the difference between a mutual insurance company and people betting on an outcome?
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#6Incredibly stupid this is allowed and will become an avenue for rampant insider trading by biotech employees. Look at the recent ChemoCentryx fraud where they settled for $35 million over misleading data and overstating results. This is going to encourage even more data manipulation.
> rampant insider trading by biotech employees
It also provides a big incentive for sabotage.
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#7[dead]
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#8Incredibly stupid this is allowed and will become an avenue for rampant insider trading by biotech employees. Look at the recent ChemoCentryx fraud where they settled for $35 million over misleading data and overstating results. This is going to encourage even more data manipulation.
> rampant insider trading by biotech employees It also provides a big incentive for sabotage.
This is one of the huge problems with allowing betting. Of course, people could collude without the formal marketplace, but just as social media provides really painful detrimental cons along with its pros, so do betting platforms.
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#9I have concerns regarding insider trading (as I certainly do regarding the stock market), but Kalshi's statement seems straightforward: "If you want to ban profiting from the failure of clinical trials, you would start with the stock market, where the financial incentive for this type of profit is orders of magnitude larger," I remember a time not too long ago when storm insurance was unavailable for large portions o…
For a mutual insurance company, everyone is betting that it's going to happen somewhere sometime, that's why they pay the premiums. There is also not "winning" and "losing", there is no particular event like a known game, and you only get paid to cover a loss. You could squint and say it's taking 100:1 odds (or whatever your coverage-to-premium ratio is), but you have the incentive to play since if an event happens TO YOU, you really LOSE, and if you don't take a bet you just don't take the bet.
Re: Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'
#10Given how much pressure there is to rig results with these markets, I see this going well.
If the hundreds of millions of dollars attached to the outcome doesn’t already create that pressure, tens of thousands connected to the prediction market won’t matter.